Article(id=1329830551307006721, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329830490300854592, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2023.08.016, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1671120000000, receivedDateStr=2022-12-16, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794985910487, onlineDateStr=2026-11-18, pubDate=1691596800000, pubDateStr=2023-08-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794985910487, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794985910487, creator=13701087609, updateTime=1794985910487, updator=13701087609, issue=Issue{id=1329830490300854592, tenantId=1146029695717560320, journalId=1319690329412173987, year='2023', volume='44', issue='8', pageStart='767', pageEnd='890', issueExtLink='null', onlineDate='null', pubDate='1691596800000', pubDateStr='2023-08-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794985895943, creator='13701087609', updateTime=1794987961153, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329839152994038236, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329830490300854592, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329839152994038237, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329830490300854592, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=865, endPage=870, ext={EN=ArticleExt(id=1329830551487361794, articleId=1329830551307006721, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=The effect of old drug sulodexide in the treatment of corona virus disease 2019, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Sulodexide has been used as an antithrombotic agent for more than 50 years. This article reviewed the mechanism of sulodexide in vascular endothelial protection, anti-thrombosis and anti-inflammation and its clinical application, discussed the role and theoretical basis of sulodexide in the treatment of corona virus disease 2019 (COVID-19), and summarized the preliminary results of clinical trials for COVID-19. Countermeasures were formulated according to the pathophysiological characteristics of covid-19 systemic inflammation and thrombosis. Sulodexide has been included in the latest guidelines for the treatment of COVID-19 by the International Society for Thrombosis and Hemostasis. Due to the unique pharmacological effects and advantages such as vascular endothelial protection and anti-inflammation, sulodexide will play an important role in combating with COVID-19.

, authors=Zhaoyang WU1, Zhanjun LI1, Wujun DONG2, *, authorsList=Zhaoyang WU, Zhanjun LI, Wujun DONG, authorCompany=null, correspAuthors=Wujun DONG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329830551718048515, articleId=1329830551307006721, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=舒洛地特老药新用在治疗新型冠状病毒肺炎中的作用, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

舒洛地特(sulodexide)作为抗血栓药物有超过50年的临床用药历史。该文主要综述舒洛地特保护血管内皮、抗血栓和抗炎的作用机制及其临床应用,探讨舒洛地特在新型冠状病毒肺炎(corona virus disease 2019,COVID-19)治疗中的作用和理论依据,并对其用于COVID-19临床研究的初步结果作总结。舒洛地特已被国际血栓和止血学会纳入最新治疗COVID-19指南,由于其具有保护血管内皮、抗炎等独特药理作用和优势,故在抗击COVID-19中发挥重要作用。

, authors=吴朝阳1, 李湛军1, 董武军2, *, authorsList=吴朝阳, 李湛军, 董武军, authorCompany=null, correspAuthors=董武军, authorNote=

吴朝阳,副主任药师,研究方向:药品质量控制。

, correspAuthorsNote=
董武军,副研究员,研究方向:药物新型递送系统设计与研发和药品技术审评。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=xV7cVgYBJ7d6IRBLMLlZKw==, magXml=hxtAvxy0zpr72p+JWvsRJA==, pdfUrl=null, pdf=XJ1zPXOlHFVhQunAvwJ94g==, pdfFileSize=1635054, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=kUJEbXrGx5xNIjHSuPWB/g==, mapNumber=null, fund=null)}, authors=[Author(id=1329830552082952971, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329830552171033357, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, authorId=1329830552082952971, language=EN, stringName=Zhaoyang WU, firstName=Zhaoyang, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.National Institute for Food and Drug Control, Beijing 102629, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329830552229753614, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, authorId=1329830552082952971, language=CN, stringName=吴朝阳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国食品药品检定研究院,北京 102629, bio={"content":"

吴朝阳,副主任药师,研究方向:药品质量控制。

"}, bioImg=null, bioContent=

吴朝阳,副主任药师,研究方向:药品质量控制。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329830551898403588, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, xref=1., ext=[AuthorCompanyExt(id=1329830551906792197, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, companyId=1329830551898403588, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.National Institute for Food and Drug Control, Beijing 102629, China), AuthorCompanyExt(id=1329830551919375110, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, companyId=1329830551898403588, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国食品药品检定研究院,北京 102629)])]), Author(id=1329830552292668176, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329830552359777042, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, authorId=1329830552292668176, language=EN, stringName=Zhanjun LI, firstName=Zhanjun, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.National Institute for Food and Drug Control, Beijing 102629, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329830552443663123, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, authorId=1329830552292668176, language=CN, stringName=李湛军, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国食品药品检定研究院,北京 102629, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329830551898403588, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, xref=1., ext=[AuthorCompanyExt(id=1329830551906792197, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, companyId=1329830551898403588, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.National Institute for Food and Drug Control, Beijing 102629, China), AuthorCompanyExt(id=1329830551919375110, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, companyId=1329830551898403588, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国食品药品检定研究院,北京 102629)])]), Author(id=1329830552506577685, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329830552586269463, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, authorId=1329830552506577685, language=EN, stringName=Wujun DONG, firstName=Wujun, middleName=null, lastName=DONG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329830552661766936, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, authorId=1329830552506577685, language=CN, stringName=董武军, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.国家药品监督管理局药品审评中心,北京 100022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329830551986483975, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, xref=2., ext=[AuthorCompanyExt(id=1329830551994872584, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, companyId=1329830551986483975, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China), AuthorCompanyExt(id=1329830552003261193, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, companyId=1329830551986483975, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.国家药品监督管理局药品审评中心,北京 100022)])])], keywords=[Keyword(id=1329830552758235929, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, language=EN, orderNo=1, keyword=sulodexide), Keyword(id=1329830552829539098, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, language=EN, orderNo=2, keyword=glycocalyx), Keyword(id=1329830552900842267, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, language=EN, orderNo=3, keyword=endothelial cells), Keyword(id=1329830552993116956, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, language=EN, orderNo=4, keyword=anti inflammatory), Keyword(id=1329830553316078365, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, language=EN, orderNo=5, keyword=antithrombotic), Keyword(id=1329830553404158750, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, language=EN, orderNo=6, keyword=corona virus disease 2019), Keyword(id=1329830553488044831, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, language=CN, orderNo=1, keyword=舒洛地特), Keyword(id=1329830555123823392, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, language=CN, orderNo=2, keyword=糖萼), Keyword(id=1329830555249652513, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, language=CN, orderNo=3, keyword=血管内皮), Keyword(id=1329830555337732898, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, language=CN, orderNo=4, keyword=抗炎), Keyword(id=1329830555476144931, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, language=CN, orderNo=5, keyword=抗血栓), Keyword(id=1329830555581002532, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, language=CN, orderNo=6, keyword=新型冠状病毒肺炎)], refs=[Reference(id=1329830555715220261, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Teuwen L, Geldhof V, Pasut A, et al. COVID-19: the vasculature unleashed[J]. Nat Rev Immunol, 2020, 20(7): 389-391., articleTitle=null, refAbstract=null), Reference(id=1329830555790717734, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=牛鹿原, 张欢, 张福先. 严重急性呼吸综合征冠状病毒2对血管内皮的影响及研究进展[J]. 中华血管外科杂志, 2021, 6(2): 133-136., articleTitle=null, refAbstract=null), Reference(id=1329830555857826599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu N, Long H, Sun J, et al. New laboratory evidence for the association between endothelial dysfunction and COVID-19 disease progression[J]. J Med Virol, 2022, 94(7): 3112-3120., articleTitle=null, refAbstract=null), Reference(id=1329830555920741160, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Schulman S, Sholzberg M, Spyropoulos AC, et al. ISTH guidelines for antithrombotic treatment in COVID-19[J]. J Thromb Haemost, 2022, 20(10): 2214-2225., articleTitle=null, refAbstract=null), Reference(id=1329830555983655721, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Luft JH. Fine structures of capillary and endocapillary layer as revealed by ruthenium red[J]. Fed Proc, 1966, 25(6): 1773-1783., articleTitle=null, refAbstract=null), Reference(id=1329830556063347498, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Nieuwdorp M, Meuwese MC, Mooij HL, et al. Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability[J]. J Appl Physiol, 2008, 104(3): 845-852., articleTitle=null, refAbstract=null), Reference(id=1329830556130456363, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Kataoka H, Ushiyama A, Akimoto Y, et al. Structural behavior of the endothelial glycocalyx is associated with pathophysiologic status in septic mice: an integrated approach to analyzing the behavior and function of the glycocalyx using both electron and fluorescence intravital microscopy[J]. Anesth Analg, 2017, 125(3): 874-883., articleTitle=null, refAbstract=null), Reference(id=1329830556193370924, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Jedlicka J, Becker BF, Chappell D. Endothelial glycocalyx[J]. Crit Care Clin, 2020, 36(2): 217-232., articleTitle=null, refAbstract=null), Reference(id=1329830556260479789, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Barry M, Pati S. Targeting repair of the vascular endothelium and glycocalyx after traumatic injury with plasma and platelet resuscitation[J]. Matrix Biol Plus, 2022, 14: 100107., articleTitle=null, refAbstract=null), Reference(id=1329830556331782958, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Abassi Z, Armaly Z, Heyman SN. Glycocalyx degradation in ischemia-reperfusion injury[J]. Am J Pathol, 2020, 190(4): 752-767., articleTitle=null, refAbstract=null), Reference(id=1329830556398891823, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Frati-Munari AC. Medical significance of endothelial glycocalyx[J]. Arch Cardiol Mex, 2013, 83(4): 303-312., articleTitle=null, refAbstract=null), Reference(id=1329830556466000688, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang X, Sun D, Song JW, et al. Endothelial cell dysfunction and glycocalyx - a vicious circle[J]. Matrix Biol, 2018, 71-72: 421-431., articleTitle=null, refAbstract=null), Reference(id=1329830556541498161, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Ramnath R, Foster RR, Qiu Y, et al. Matrix metalloproteinase 9-mediated shedding of syndecan 4 in response to tumor necrosis factor alpha: a contributor to endothelial cell glycocalyx dysfunction[J]. FASEB J, 2014, 28(11): 4686-4699., articleTitle=null, refAbstract=null), Reference(id=1329830556604412722, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Strunden MS, Bornscheuer A, Schuster A, et al. Glycocalyx degradation causes microvascular perfusion failure in the ex vivo perfused mouse lung: hydroxyethyl starch 130/0.4 pretreatment attenuates this response[J]. Shock, 2012, 38(5): 559-566., articleTitle=null, refAbstract=null), Reference(id=1329830556667327283, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Milusev A, Rieben R, Sorvillo N. The endothelial glycocalyx: a possible therapeutic target in cardiovascular disorders[J]. Front Cardiovasc Med, 2022, 9: 897087., articleTitle=null, refAbstract=null), Reference(id=1329830556734436148, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus[J]. Diabetologia, 2010, 53(12): 2646-2655., articleTitle=null, refAbstract=null), Reference(id=1329830556788962101, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Hoppensteadt DA, Fareed J. Pharmacological profile of sulodexide[J]. Int Angiol, 2014, 33(3): 229., articleTitle=null, refAbstract=null), Reference(id=1329830556872848182, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Cosmi B, Cini M, Legnani C, et al. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans[J]. Thromb Res, 2003, 109(5-6): 333-339., articleTitle=null, refAbstract=null), Reference(id=1329830556935762743, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Cosmi B, Agnelli G, Young E, et al. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate[J]. Thromb Haemost, 1993, 70(3): 443-447., articleTitle=null, refAbstract=null), Reference(id=1329830557007065912, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Adiguzel C, Iqbal O, Hoppensteadt D, et al. Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide[J]. Clin Appl Thromb Hemost, 2009, 15(5): 501-511., articleTitle=null, refAbstract=null), Reference(id=1329830557078369081, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Barbanti M, Guizzardi S, Calanni F, et al. Antithrombotic and thrombolytic activity of sulodexide in rats[J]. Int J Clin Lab Res, 1992, 22(3): 179-184., articleTitle=null, refAbstract=null), Reference(id=1329830557162255162, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Andreozzi GM, Bignamini AA, Davi G, et al. Sulodexide for the prevention of recurrent venous thromboembolism: the sulodexide in secondary prevention of recurrent deep vein thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial[J]. Circulation, 2015, 132(20): 1891-1897., articleTitle=null, refAbstract=null), Reference(id=1329830557241946939, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Palareti G, Legnani C, Antonucci E, et al. Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism[J]. Intern Emerg Med, 2021, 16(2): 359-368., articleTitle=null, refAbstract=null), Reference(id=1329830557330027324, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Sohn SH, Kim TS, Kim JW, et al. Anti-thrombotic and anti-inflammatory activity of sulodexide compared to aspirin in the rat model[J]. Clin Hemorheol Microcirc, 2021, 77(4): 435-442., articleTitle=null, refAbstract=null), Reference(id=1329830557413913405, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment[J]. Drug Des Devel Ther, 2013, 8: 49-65., articleTitle=null, refAbstract=null), Reference(id=1329830557510382398, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Andreozzi GM. Sulodexide in the treatment of chronic venous disease[J]. Am J Cardiovasc Drugs, 2012, 12(2): 73-81., articleTitle=null, refAbstract=null), Reference(id=1329830557598462783, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Andreozzi GM. Editorial: sulodexide, an old drug with recent renewed interest[J]. Curr Vasc Pharmacol, 2013, 11(3): 352-353., articleTitle=null, refAbstract=null), Reference(id=1329830557732680512, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Mannello F, Ligi D, Canale M, et al. Sulodexide down-regulates the release of cytokines, chemokines, and leukocyte colony stimulating factors from human macrophages: role of glycosaminoglycans in inflammatory pathways of chronic venous disease[J]. Curr Vasc Pharmacol, 2014, 12(1): 173-185., articleTitle=null, refAbstract=null), Reference(id=1329830557791400769, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Raffetto JD, Khalil RA. Mechanisms of lower extremity vein dysfunction in chronic venous disease and implications in management of varicose veins[J]. Vessel Plus, 2021, 5: 36., articleTitle=null, refAbstract=null), Reference(id=1329830557858509634, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Song JW, Zullo JA, Liveris D, et al. Therapeutic restoration of endothelial glycocalyx in sepsis[J]. J Pharmacol Exp Ther, 2017, 361(1): 115-121., articleTitle=null, refAbstract=null), Reference(id=1329830557929812803, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Rovas A, Seidel LM, Vink H, et al. Association of sublingual microcirculation parameters and endothelial glycocalyx dimensions in resuscitated sepsis[J]. Crit Care, 2019, 23(1): 260., articleTitle=null, refAbstract=null), Reference(id=1329830558005310276, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Song JW, Zullo J, Lipphardt M, et al. Endothelial glycocalyx-the battleground for complications of sepsis and kidney injury[J]. Nephrol Dial Transplant, 2018, 33(2): 203-211., articleTitle=null, refAbstract=null), Reference(id=1329830559645283141, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Drost CC, Rovas A, Kümpers P. Protection and rebuilding of the endothelial glycocalyx in sepsis – science or fiction?[J]. Matrix Biol Plus, 2021, 12: 100091., articleTitle=null, refAbstract=null), Reference(id=1329830559733363526, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=LaRiviere WB, Schmidt EP. The pulmonary endothelial glycocalyx in ARDS: a critical role for heparan sulfate[J]. Curr Top Membr, 2018, 82: 33-52., articleTitle=null, refAbstract=null), Reference(id=1329830559813055303, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19[J]. N Engl J Med, 2020, 383(2): 120-128., articleTitle=null, refAbstract=null), Reference(id=1329830559880164168, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19[J]. Lancet, 2020, 395(10234): 1417-1418., articleTitle=null, refAbstract=null), Reference(id=1329830560047936329, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Qin Z, Liu F, Blair R, et al. Endothelial cell infection and dysfunction, immune activation in severe COVID-19[J]. Theranostics, 2021, 11(16): 8076-8091., articleTitle=null, refAbstract=null), Reference(id=1329830560102462282, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19[J]. Inflamm Res, 2020, 69(12): 1181-1189., articleTitle=null, refAbstract=null), Reference(id=1329830560156988235, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Iba T, Levy JH, Levi M, et al. Coagulopathy in COVID-19[J]. J Thromb Haemost, 2020, 18(9): 2103-2109., articleTitle=null, refAbstract=null), Reference(id=1329830560219902796, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Rodríguez C, Luque N, Blanco I, et al. Pulmonary endothelial dysfunction and thrombotic complications in patients with COVID-19[J]. Am J Respir Cell Mol Biol, 2021, 64(4): 407-415., articleTitle=null, refAbstract=null), Reference(id=1329830560324760397, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Zha D, Fu M, Qian Y. Vascular endothelial glycocalyx damage and potential targeted therapy in COVID-19[J]. Cells, 2022, 11(12): 1972., articleTitle=null, refAbstract=null), Reference(id=1329830560383480654, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Smadja DM, Mentzer SJ, Fontenay M, et al. COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects[J]. Angiogenesis, 2021, 24(4): 755-788., articleTitle=null, refAbstract=null), Reference(id=1329830560438006607, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Okada H, Yoshida S, Hara A, et al. Vascular endothelial injury exacerbates coronavirus disease 2019: the role of endothelial glycocalyx protection[J]. Microcirculation, 2021, 28(3): e12654., articleTitle=null, refAbstract=null), Reference(id=1329830560505115472, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=Yamaoka-Tojo M. Vascular endothelial glycocalyx damage in COVID-19[J]. Int J Mol Sci, 2020, 21(24): 9712., articleTitle=null, refAbstract=null), Reference(id=1329830560572224337, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Yamaoka-Tojo M. Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19[J]. Biomed J, 2020, 43(5): 399-413., articleTitle=null, refAbstract=null), Reference(id=1329830560635138898, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=Magnani HN. Rationale for the role of heparin and related GAG antithrombotics in COVID-19 infection[J]. Clin Appl Thromb Hemost, 2021, 27: 1076029620977702., articleTitle=null, refAbstract=null), Reference(id=1329830560719024979, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=Szolnoky G. Sulodexide may be a real alternative to low molecular weight heparins in the prevention of COVID-19 induced vascular complications[J]. Dermatol Ther, 2020, 33(6): e14437., articleTitle=null, refAbstract=null), Reference(id=1329830560786133844, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=Schulman S, Harenberg J. Anticoagulant treatment of COVID-19 as early as possible - sulodexide and perspectives[J]. Thromb Haemost, 2021, 121(7): 849-853., articleTitle=null, refAbstract=null), Reference(id=1329830560870019925, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=Gonzalez-Ochoa AJ, Raffetto JD, Hernández AG, et al. Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial[J]. Thromb Haemost, 2021, 121(7): 944-954., articleTitle=null, refAbstract=null), Reference(id=1329830560962294614, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=Melkumyants A, Buryachkovskaya L, Lomakin N, et al. Effect of sulodexide on circulating blood cells in patients with mild COVID-19[J]. J Clin Med, 2022, 11(7): 1995., articleTitle=null, refAbstract=null), Reference(id=1329830561050374999, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=null, refType=null, unstructuredReference=Charfeddine S, Ibnhadjamor H, Jdidi J, et al. Sulodexide significantly improves endothelial dysfunction and alleviates chest pain and palpitations in patients with long-COVID-19: insights from TUN-EndCOV study[J]. Front Cardiovasc Med, 2022, 9: 866113., articleTitle=null, refAbstract=null), Reference(id=1329830561146843992, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[52], rfOrder=51, authorNames=null, journalName=null, refType=null, unstructuredReference=Pompilio G, Integlia D, Raffetto J, et al. Comparative efficacy and safety of sulodexide and other extended anticoagulation treatments for prevention of recurrent venous thromboembolism: a bayesian network meta-analysis[J]. TH Open, 2020, 4(2): e80-e93., articleTitle=null, refAbstract=null), Reference(id=1329830561218147161, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[53], rfOrder=52, authorNames=null, journalName=null, refType=null, unstructuredReference=Veraldi N, Guerrini M, Urso E, et al. Fine structural characterization of sulodexide[J]. J Pharm Biomed Anal, 2018, 156: 67-79., articleTitle=null, refAbstract=null), Reference(id=1329830561293644634, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[54], rfOrder=53, authorNames=null, journalName=null, refType=null, unstructuredReference=Pepi LE, Sanderson P, Stickney M, et al. Developments in mass spectrometry for glycosaminoglycan analysis: a review[J]. Mol Cell Proteomics, 2021, 20: 100025., articleTitle=null, refAbstract=null), Reference(id=1329830561356559195, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[55], rfOrder=54, authorNames=null, journalName=null, refType=null, unstructuredReference=Song Y, Zhang F, Linhardt RJ. Analysis of the glycosa-minoglycan chains of proteoglycans[J]. J Histochem Cytochem, 2021, 69(2): 121-135., articleTitle=null, refAbstract=null), Reference(id=1329830561440445276, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[56], rfOrder=55, authorNames=null, journalName=null, refType=null, unstructuredReference=王亚敏. 舒洛地特研究进展及临床应用[J]. 中国临床药理学与治疗学, 2010, 15(1): 109-115., articleTitle=null, refAbstract=null), Reference(id=1329830561532719965, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[57], rfOrder=56, authorNames=null, journalName=null, refType=null, unstructuredReference=张娟, 冷佳蔚, 李水仙, 等. 舒洛地特注射液非临床安全性评价[J]. 中国药业, 2021, 30(6): 28-31., articleTitle=null, refAbstract=null), Reference(id=1329830561608217438, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[58], rfOrder=57, authorNames=null, journalName=null, refType=null, unstructuredReference=王悦, 范慧红. 多糖类生化药物的质控策略与质控技术研究进展[J]. 中国药学杂志, 2021, 56(1): 8-12., articleTitle=null, refAbstract=null), Reference(id=1329830561704686431, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[59], rfOrder=58, authorNames=null, journalName=null, refType=null, unstructuredReference=石靖, 陈思. 低分子量肝素仿制研究技术要求和监管理念的进展[J]. 国际药学研究杂志, 2018, 45(11): 852-857., articleTitle=null, refAbstract=null), Reference(id=1329830561838904160, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[60], rfOrder=59, authorNames=null, journalName=null, refType=null, unstructuredReference=李湛军, 徐康森. 生化药物质量控制中生物测定的作用与局限[J]. 药物分析杂志, 2007, (2): 297-301., articleTitle=null, refAbstract=null), Reference(id=1329830561977316193, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[61], rfOrder=60, authorNames=null, journalName=null, refType=null, unstructuredReference=赵娜, 石靖. 仿制药一致性评价中杂质研究的常见问题探讨[J]. 中国医药工业杂志, 2021, 52(5): 703-708., articleTitle=null, refAbstract=null), Reference(id=1329830562065396578, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[62], rfOrder=61, authorNames=null, journalName=null, refType=null, unstructuredReference=张玉琥. 仿制药有关物质研究的特点及研究思路[J]. 中国执业药师, 2009, 6(8): 31-34., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329830551898403588, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, xref=1., ext=[AuthorCompanyExt(id=1329830551906792197, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, companyId=1329830551898403588, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.National Institute for Food and Drug Control, Beijing 102629, China), AuthorCompanyExt(id=1329830551919375110, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, companyId=1329830551898403588, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国食品药品检定研究院,北京 102629)]), AuthorCompany(id=1329830551986483975, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, xref=2., ext=[AuthorCompanyExt(id=1329830551994872584, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, companyId=1329830551986483975, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China), AuthorCompanyExt(id=1329830552003261193, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, companyId=1329830551986483975, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.国家药品监督管理局药品审评中心,北京 100022)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.08.016, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.08.016, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2023.08.016, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2023.08.016, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1691596800000, fullTextJson=null, articleText=null, reference=null)
收藏切换
舒洛地特老药新用在治疗新型冠状病毒肺炎中的作用
吴朝阳 1 , 李湛军 1 , 董武军 2, *
世界临床药物 | 综述评论 2023,44(8): 865-870
收起
收藏切换
世界临床药物 |综述评论 2023 , 44 (8) : 865 -870
舒洛地特老药新用在治疗新型冠状病毒肺炎中的作用
全屏
[Author(id=1329830552082952971, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329830552171033357, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, authorId=1329830552082952971, language=EN, stringName=Zhaoyang WU, firstName=Zhaoyang, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.National Institute for Food and Drug Control, Beijing 102629, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329830552229753614, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, authorId=1329830552082952971, language=CN, stringName=吴朝阳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国食品药品检定研究院,北京 102629, bio={"content":"

吴朝阳,副主任药师,研究方向:药品质量控制。

"}, bioImg=null, bioContent=

吴朝阳,副主任药师,研究方向:药品质量控制。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329830551898403588, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, xref=1., ext=[AuthorCompanyExt(id=1329830551906792197, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, companyId=1329830551898403588, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.National Institute for Food and Drug Control, Beijing 102629, China), AuthorCompanyExt(id=1329830551919375110, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, companyId=1329830551898403588, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国食品药品检定研究院,北京 102629)])]), Author(id=1329830552292668176, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329830552359777042, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, authorId=1329830552292668176, language=EN, stringName=Zhanjun LI, firstName=Zhanjun, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.National Institute for Food and Drug Control, Beijing 102629, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329830552443663123, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, authorId=1329830552292668176, language=CN, stringName=李湛军, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国食品药品检定研究院,北京 102629, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329830551898403588, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, xref=1., ext=[AuthorCompanyExt(id=1329830551906792197, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, companyId=1329830551898403588, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.National Institute for Food and Drug Control, Beijing 102629, China), AuthorCompanyExt(id=1329830551919375110, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, companyId=1329830551898403588, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国食品药品检定研究院,北京 102629)])]), Author(id=1329830552506577685, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329830552586269463, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, authorId=1329830552506577685, language=EN, stringName=Wujun DONG, firstName=Wujun, middleName=null, lastName=DONG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329830552661766936, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, authorId=1329830552506577685, language=CN, stringName=董武军, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.国家药品监督管理局药品审评中心,北京 100022, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329830551986483975, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, xref=2., ext=[AuthorCompanyExt(id=1329830551994872584, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, companyId=1329830551986483975, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China), AuthorCompanyExt(id=1329830552003261193, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329830551307006721, companyId=1329830551986483975, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.国家药品监督管理局药品审评中心,北京 100022)])])]
吴朝阳1, 李湛军1, 董武军2, *
作者信息
  • 1.中国食品药品检定研究院,北京 102629
  • 2.国家药品监督管理局药品审评中心,北京 100022
通讯作者:
董武军,副研究员,研究方向:药物新型递送系统设计与研发和药品技术审评。
作者简介:

吴朝阳,副主任药师,研究方向:药品质量控制。

The effect of old drug sulodexide in the treatment of corona virus disease 2019
Zhaoyang WU1, Zhanjun LI1, Wujun DONG2, *
Affiliations
  • 1.National Institute for Food and Drug Control, Beijing 102629, China
  • 2.Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China
出版时间: 2023-08-10 doi: 10.13683/j.wph.2023.08.016
文章导航
收藏切换

舒洛地特(sulodexide)作为抗血栓药物有超过50年的临床用药历史。该文主要综述舒洛地特保护血管内皮、抗血栓和抗炎的作用机制及其临床应用,探讨舒洛地特在新型冠状病毒肺炎(corona virus disease 2019,COVID-19)治疗中的作用和理论依据,并对其用于COVID-19临床研究的初步结果作总结。舒洛地特已被国际血栓和止血学会纳入最新治疗COVID-19指南,由于其具有保护血管内皮、抗炎等独特药理作用和优势,故在抗击COVID-19中发挥重要作用。

舒洛地特  /  糖萼  /  血管内皮  /  抗炎  /  抗血栓  /  新型冠状病毒肺炎

Sulodexide has been used as an antithrombotic agent for more than 50 years. This article reviewed the mechanism of sulodexide in vascular endothelial protection, anti-thrombosis and anti-inflammation and its clinical application, discussed the role and theoretical basis of sulodexide in the treatment of corona virus disease 2019 (COVID-19), and summarized the preliminary results of clinical trials for COVID-19. Countermeasures were formulated according to the pathophysiological characteristics of covid-19 systemic inflammation and thrombosis. Sulodexide has been included in the latest guidelines for the treatment of COVID-19 by the International Society for Thrombosis and Hemostasis. Due to the unique pharmacological effects and advantages such as vascular endothelial protection and anti-inflammation, sulodexide will play an important role in combating with COVID-19.

sulodexide  /  glycocalyx  /  endothelial cells  /  anti inflammatory  /  antithrombotic  /  corona virus disease 2019
吴朝阳, 李湛军, 董武军. 舒洛地特老药新用在治疗新型冠状病毒肺炎中的作用. 世界临床药物, 2023 , 44 (8) : 865 -870 . DOI: 10.13683/j.wph.2023.08.016
Zhaoyang WU, Zhanjun LI, Wujun DONG. The effect of old drug sulodexide in the treatment of corona virus disease 2019[J]. World Clinical Drug, 2023 , 44 (8) : 865 -870 . DOI: 10.13683/j.wph.2023.08.016

参考文献 引证文献
排序方式:
[1]
Teuwen L, Geldhof V, Pasut A, et al. COVID-19: the vasculature unleashed[J]. Nat Rev Immunol, 2020, 20(7): 389-391.
[2]
牛鹿原, 张欢, 张福先. 严重急性呼吸综合征冠状病毒2对血管内皮的影响及研究进展[J]. 中华血管外科杂志, 2021, 6(2): 133-136.
[3]
Liu N, Long H, Sun J, et al. New laboratory evidence for the association between endothelial dysfunction and COVID-19 disease progression[J]. J Med Virol, 2022, 94(7): 3112-3120.
[4]
Schulman S, Sholzberg M, Spyropoulos AC, et al. ISTH guidelines for antithrombotic treatment in COVID-19[J]. J Thromb Haemost, 2022, 20(10): 2214-2225.
[5]
Luft JH. Fine structures of capillary and endocapillary layer as revealed by ruthenium red[J]. Fed Proc, 1966, 25(6): 1773-1783.
[6]
Nieuwdorp M, Meuwese MC, Mooij HL, et al. Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability[J]. J Appl Physiol, 2008, 104(3): 845-852.
[7]
Kataoka H, Ushiyama A, Akimoto Y, et al. Structural behavior of the endothelial glycocalyx is associated with pathophysiologic status in septic mice: an integrated approach to analyzing the behavior and function of the glycocalyx using both electron and fluorescence intravital microscopy[J]. Anesth Analg, 2017, 125(3): 874-883.
[8]
Jedlicka J, Becker BF, Chappell D. Endothelial glycocalyx[J]. Crit Care Clin, 2020, 36(2): 217-232.
[9]
Barry M, Pati S. Targeting repair of the vascular endothelium and glycocalyx after traumatic injury with plasma and platelet resuscitation[J]. Matrix Biol Plus, 2022, 14: 100107.
[10]
Abassi Z, Armaly Z, Heyman SN. Glycocalyx degradation in ischemia-reperfusion injury[J]. Am J Pathol, 2020, 190(4): 752-767.
[11]
Frati-Munari AC. Medical significance of endothelial glycocalyx[J]. Arch Cardiol Mex, 2013, 83(4): 303-312.
[12]
Zhang X, Sun D, Song JW, et al. Endothelial cell dysfunction and glycocalyx - a vicious circle[J]. Matrix Biol, 2018, 71-72: 421-431.
[13]
Ramnath R, Foster RR, Qiu Y, et al. Matrix metalloproteinase 9-mediated shedding of syndecan 4 in response to tumor necrosis factor alpha: a contributor to endothelial cell glycocalyx dysfunction[J]. FASEB J, 2014, 28(11): 4686-4699.
[14]
Strunden MS, Bornscheuer A, Schuster A, et al. Glycocalyx degradation causes microvascular perfusion failure in the ex vivo perfused mouse lung: hydroxyethyl starch 130/0.4 pretreatment attenuates this response[J]. Shock, 2012, 38(5): 559-566.
[15]
Milusev A, Rieben R, Sorvillo N. The endothelial glycocalyx: a possible therapeutic target in cardiovascular disorders[J]. Front Cardiovasc Med, 2022, 9: 897087.
[16]
Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus[J]. Diabetologia, 2010, 53(12): 2646-2655.
[17]
Hoppensteadt DA, Fareed J. Pharmacological profile of sulodexide[J]. Int Angiol, 2014, 33(3): 229.
[18]
Cosmi B, Cini M, Legnani C, et al. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans[J]. Thromb Res, 2003, 109(5-6): 333-339.
[19]
Cosmi B, Agnelli G, Young E, et al. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate[J]. Thromb Haemost, 1993, 70(3): 443-447.
[20]
Adiguzel C, Iqbal O, Hoppensteadt D, et al. Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide[J]. Clin Appl Thromb Hemost, 2009, 15(5): 501-511.
[21]
Barbanti M, Guizzardi S, Calanni F, et al. Antithrombotic and thrombolytic activity of sulodexide in rats[J]. Int J Clin Lab Res, 1992, 22(3): 179-184.
[22]
Andreozzi GM, Bignamini AA, Davi G, et al. Sulodexide for the prevention of recurrent venous thromboembolism: the sulodexide in secondary prevention of recurrent deep vein thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial[J]. Circulation, 2015, 132(20): 1891-1897.
[23]
Palareti G, Legnani C, Antonucci E, et al. Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism[J]. Intern Emerg Med, 2021, 16(2): 359-368.
[24]
Sohn SH, Kim TS, Kim JW, et al. Anti-thrombotic and anti-inflammatory activity of sulodexide compared to aspirin in the rat model[J]. Clin Hemorheol Microcirc, 2021, 77(4): 435-442.
[25]
Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment[J]. Drug Des Devel Ther, 2013, 8: 49-65.
[26]
Andreozzi GM. Sulodexide in the treatment of chronic venous disease[J]. Am J Cardiovasc Drugs, 2012, 12(2): 73-81.
[27]
Andreozzi GM. Editorial: sulodexide, an old drug with recent renewed interest[J]. Curr Vasc Pharmacol, 2013, 11(3): 352-353.
[28]
Mannello F, Ligi D, Canale M, et al. Sulodexide down-regulates the release of cytokines, chemokines, and leukocyte colony stimulating factors from human macrophages: role of glycosaminoglycans in inflammatory pathways of chronic venous disease[J]. Curr Vasc Pharmacol, 2014, 12(1): 173-185.
[29]
Raffetto JD, Khalil RA. Mechanisms of lower extremity vein dysfunction in chronic venous disease and implications in management of varicose veins[J]. Vessel Plus, 2021, 5: 36.
[30]
Song JW, Zullo JA, Liveris D, et al. Therapeutic restoration of endothelial glycocalyx in sepsis[J]. J Pharmacol Exp Ther, 2017, 361(1): 115-121.
[31]
Rovas A, Seidel LM, Vink H, et al. Association of sublingual microcirculation parameters and endothelial glycocalyx dimensions in resuscitated sepsis[J]. Crit Care, 2019, 23(1): 260.
[32]
Song JW, Zullo J, Lipphardt M, et al. Endothelial glycocalyx-the battleground for complications of sepsis and kidney injury[J]. Nephrol Dial Transplant, 2018, 33(2): 203-211.
[33]
Drost CC, Rovas A, Kümpers P. Protection and rebuilding of the endothelial glycocalyx in sepsis – science or fiction?[J]. Matrix Biol Plus, 2021, 12: 100091.
[34]
LaRiviere WB, Schmidt EP. The pulmonary endothelial glycocalyx in ARDS: a critical role for heparan sulfate[J]. Curr Top Membr, 2018, 82: 33-52.
[35]
Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19[J]. N Engl J Med, 2020, 383(2): 120-128.
[36]
Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19[J]. Lancet, 2020, 395(10234): 1417-1418.
[37]
Qin Z, Liu F, Blair R, et al. Endothelial cell infection and dysfunction, immune activation in severe COVID-19[J]. Theranostics, 2021, 11(16): 8076-8091.
[38]
Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19[J]. Inflamm Res, 2020, 69(12): 1181-1189.
[39]
Iba T, Levy JH, Levi M, et al. Coagulopathy in COVID-19[J]. J Thromb Haemost, 2020, 18(9): 2103-2109.
[40]
Rodríguez C, Luque N, Blanco I, et al. Pulmonary endothelial dysfunction and thrombotic complications in patients with COVID-19[J]. Am J Respir Cell Mol Biol, 2021, 64(4): 407-415.
[41]
Zha D, Fu M, Qian Y. Vascular endothelial glycocalyx damage and potential targeted therapy in COVID-19[J]. Cells, 2022, 11(12): 1972.
[42]
Smadja DM, Mentzer SJ, Fontenay M, et al. COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects[J]. Angiogenesis, 2021, 24(4): 755-788.
[43]
Okada H, Yoshida S, Hara A, et al. Vascular endothelial injury exacerbates coronavirus disease 2019: the role of endothelial glycocalyx protection[J]. Microcirculation, 2021, 28(3): e12654.
[44]
Yamaoka-Tojo M. Vascular endothelial glycocalyx damage in COVID-19[J]. Int J Mol Sci, 2020, 21(24): 9712.
[45]
Yamaoka-Tojo M. Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19[J]. Biomed J, 2020, 43(5): 399-413.
[46]
Magnani HN. Rationale for the role of heparin and related GAG antithrombotics in COVID-19 infection[J]. Clin Appl Thromb Hemost, 2021, 27: 1076029620977702.
[47]
Szolnoky G. Sulodexide may be a real alternative to low molecular weight heparins in the prevention of COVID-19 induced vascular complications[J]. Dermatol Ther, 2020, 33(6): e14437.
[48]
Schulman S, Harenberg J. Anticoagulant treatment of COVID-19 as early as possible - sulodexide and perspectives[J]. Thromb Haemost, 2021, 121(7): 849-853.
[49]
Gonzalez-Ochoa AJ, Raffetto JD, Hernández AG, et al. Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial[J]. Thromb Haemost, 2021, 121(7): 944-954.
[50]
Melkumyants A, Buryachkovskaya L, Lomakin N, et al. Effect of sulodexide on circulating blood cells in patients with mild COVID-19[J]. J Clin Med, 2022, 11(7): 1995.
[51]
Charfeddine S, Ibnhadjamor H, Jdidi J, et al. Sulodexide significantly improves endothelial dysfunction and alleviates chest pain and palpitations in patients with long-COVID-19: insights from TUN-EndCOV study[J]. Front Cardiovasc Med, 2022, 9: 866113.
[52]
Pompilio G, Integlia D, Raffetto J, et al. Comparative efficacy and safety of sulodexide and other extended anticoagulation treatments for prevention of recurrent venous thromboembolism: a bayesian network meta-analysis[J]. TH Open, 2020, 4(2): e80-e93.
[53]
Veraldi N, Guerrini M, Urso E, et al. Fine structural characterization of sulodexide[J]. J Pharm Biomed Anal, 2018, 156: 67-79.
[54]
Pepi LE, Sanderson P, Stickney M, et al. Developments in mass spectrometry for glycosaminoglycan analysis: a review[J]. Mol Cell Proteomics, 2021, 20: 100025.
[55]
Song Y, Zhang F, Linhardt RJ. Analysis of the glycosa-minoglycan chains of proteoglycans[J]. J Histochem Cytochem, 2021, 69(2): 121-135.
[56]
王亚敏. 舒洛地特研究进展及临床应用[J]. 中国临床药理学与治疗学, 2010, 15(1): 109-115.
[57]
张娟, 冷佳蔚, 李水仙, 等. 舒洛地特注射液非临床安全性评价[J]. 中国药业, 2021, 30(6): 28-31.
[58]
王悦, 范慧红. 多糖类生化药物的质控策略与质控技术研究进展[J]. 中国药学杂志, 2021, 56(1): 8-12.
[59]
石靖, 陈思. 低分子量肝素仿制研究技术要求和监管理念的进展[J]. 国际药学研究杂志, 2018, 45(11): 852-857.
[60]
李湛军, 徐康森. 生化药物质量控制中生物测定的作用与局限[J]. 药物分析杂志, 2007, (2): 297-301.
[61]
赵娜, 石靖. 仿制药一致性评价中杂质研究的常见问题探讨[J]. 中国医药工业杂志, 2021, 52(5): 703-708.
[62]
张玉琥. 仿制药有关物质研究的特点及研究思路[J]. 中国执业药师, 2009, 6(8): 31-34.
2023年第44卷第8期
14
3
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2023.08.016
  • 接收时间:2022-12-16
  • 首发时间:2026-11-18
  • 出版时间:2023-08-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2022-12-16
基金
作者信息
    1.中国食品药品检定研究院,北京 102629
    2.国家药品监督管理局药品审评中心,北京 100022

通讯作者:

董武军,副研究员,研究方向:药物新型递送系统设计与研发和药品技术审评。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2023.08.016
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏